Implication of hepatokines in metabolic disorders and cardiovascular diseases

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

The liver is a central regulator of systemic energy homeostasis and has a pivotal role in glucose and lipid metabolism. Impaired gluconeogenesis and dyslipidemia are often observed in patients with nonalcoholic fatty liver disease (NAFLD). The liver is now recognized to be an endocrine organ that secretes hepatokines, which are proteins that regulate systemic metabolism and energy homeostasis. Hepatokines are known to contribute to the pathogenesis of metabolic syndrome, NAFLD, type 2 diabetes (T2DM), and cardiovascular diseases (CVDs). In this review, we focus on the roles of two major hepatokines, fetuin-A and fibroblast growth factor 21 (FGF21), as well as recently-redefined hepatokines, such as selenoprotein P, angiopoietin-like protein 4 (ANGPTL4), and leukocyte cell-derived chemotaxin 2 (LECT2). We also assess the biology and molecular mechanisms of hepatokines in the context of their potential as therapeutic targets for metabolic disorders and cardiovascular diseases.

Original languageEnglish
Pages (from-to)108-113
Number of pages6
JournalBBA Clinical
Volume5
DOIs
Publication statusPublished - 2016 Jun 1

Keywords

  • Angiopoietin-like protein 4
  • Fetuin-A
  • Fibroblast growth factor 21
  • Hepatokine
  • Leukocyte cell-derived chemotaxin 2
  • Selenoprotein P

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Implication of hepatokines in metabolic disorders and cardiovascular diseases'. Together they form a unique fingerprint.

  • Cite this